Page last updated: 2024-09-04

atrasentan and losartan

atrasentan has been researched along with losartan in 7 studies

Compound Research Comparison

Studies
(atrasentan)
Trials
(atrasentan)
Recent Studies (post-2010)
(atrasentan)
Studies
(losartan)
Trials
(losartan)
Recent Studies (post-2010) (losartan)
358411087,2311,2452,118

Protein Interaction Comparison

ProteinTaxonomyatrasentan (IC50)losartan (IC50)
Bile salt export pumpHomo sapiens (human)9.01
Cytochrome P450 2C9 Homo sapiens (human)2.882
Angiotensin-converting enzyme Homo sapiens (human)0.019
Atrial natriuretic peptide receptor 3Homo sapiens (human)0.0018
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.019
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)0.0247
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)0.0234
Adenosine receptor A2aRattus norvegicus (Norway rat)0.0032
Type-1 angiotensin II receptorHomo sapiens (human)0.047
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)0.025
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)0.0118
Type-2 angiotensin II receptorHomo sapiens (human)0.019
Platelet glycoprotein VIHomo sapiens (human)4
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)1.1481
Type-1 angiotensin II receptorCavia porcellus (domestic guinea pig)0.018
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.2884

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Boemke, W; Francis, RC; Höhne, C; Kaczmarczyk, G1
Boemke, W; Francis, RC; Höhne, C; Kaisers, U; Klein, A; Pickerodt, P1
Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F1
Certíková Chábová, V; Červenka, L; Husková, Z; Kramer, HJ; Kujal, P; Skaroupková, P; Tesař, V; Vaněčková, I; Vaňourková, Z; Vernerová, Z1
Andress, DL; Bijlsma, MJ; de Zeeuw, D; Heerspink, HJ; Kröpelin, TF; Parving, HH; Persson, F1
El-Din, MM; El-Mas, MM; Elmallah, AI; Khedr, MM; Nasser, SA; Sabra, R1
Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA1

Other Studies

7 other study(ies) available for atrasentan and losartan

ArticleYear
Effect of angiotensin II and endothelin-1 receptor blockade on the haemodynamic and hormonal changes after acute blood loss and after retransfusion in conscious dogs.
    Acta physiologica Scandinavica, 2004, Volume: 180, Issue:4

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Transfusion; Cardiac Output; Dogs; Endothelin-1; Epinephrine; Female; Glomerular Filtration Rate; Hemodynamics; Hemorrhage; Losartan; Norepinephrine; Pyrrolidines; Receptor, Endothelin A; Stroke Volume; Urine; Vascular Resistance; Vasopressins

2004
ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist.
    Canadian journal of physiology and pharmacology, 2008, Volume: 86, Issue:6

    Topics: Anesthesia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Blood Pressure; Dogs; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hemodynamics; Hemorrhage; Losartan; Pyrrolidines; Vascular Resistance; Vasoconstriction; Vasopressins; Xenon

2008
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.
    European journal of pharmacology, 2009, Apr-01, Volume: 607, Issue:1-3

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Endothelin-1; Hydralazine; Hypertension, Malignant; Losartan; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renal Insufficiency

2009
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
    Kidney & blood pressure research, 2012, Volume: 35, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Hypertension, Renal; Indoles; Kidney; Losartan; Male; Nephrectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Renal Insufficiency, Chronic; Renin-Angiotensin System; Survival Analysis; Treatment Outcome

2012
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
    Clinical journal of the American Society of Nephrology : CJASN, 2015, Mar-06, Volume: 10, Issue:3

    Topics: Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrasentan; Bone Density Conservation Agents; Diabetic Nephropathies; Endothelin Receptor Antagonists; Ergocalciferols; Female; Fumarates; Humans; Losartan; Male; Middle Aged; Office Visits; Pyrrolidines; Randomized Controlled Trials as Topic; Research Design; Statistics as Topic; Urine Specimen Collection

2015
Facilitation by the renin-angiotensin system of cyclosporine-evoked hypertension in rats: Role of arterial baroreflexes and vasoreactivity.
    Life sciences, 2016, Oct-15, Volume: 163

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Angiotensin II; Animals; Aorta; Atrasentan; Baroreflex; Blood Pressure; Captopril; Cyclosporine; Hypertension; Indomethacin; Losartan; Male; Naphthalenes; Nitric Oxide Synthase Type III; Nitroprusside; Oligopeptides; Phenylephrine; Piperidines; Propionates; Pyrrolidines; Rats; Renin-Angiotensin System; Vasoconstriction; Vasodilation

2016
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
    American journal of physiology. Renal physiology, 2020, 05-01, Volume: 318, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Losartan; Mice; Phosphorylation; Podocytes; Proteinuria; Renin-Angiotensin System; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases

2020